A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Upadacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-EARLY
- Sponsors AbbVie; AbbVie Germany
Most Recent Events
- 29 Jul 2024 Results assessing efficacy over 5 years, published in the Arthritis Research and Therapy.
- 15 Nov 2023 Results (n=945) reporting safety and efficacy through five years from OTE portion of this trial presented at the ACR Convergence 2023
- 12 Jun 2023 Results of post-hoc pooled analysis of 6 studies (NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343) assessing potential risk of upadacitinib in a similar RA population, published in the Annals of the Rheumatic Diseases.